Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City-Reference-Cited by-同舟云学术

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Published:2018-03-27 Issue:11 Volume:22 Page:3627-3636
ISSN:1090-7165
Container-title:AIDS and Behavior
language:en
Short-container-title:AIDS Behav

Author:

Rael Christine Tagliaferri,Martinez Michelle,Giguere Rebecca,Bockting Walter,MacCrate Caitlin,Mellman Will,Valente Pablo,Greene George J.,Sherman Susan,Footer Katherine H. A.,D’Aquila Richard T.,Carballo-Diéguez Alex

Funder

National Institute of Mental Health

Mac AIDS Fund

National Institute of Child Health and Human Development

National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology

Link

http://link.springer.com/article/10.1007/s10461-018-2102-9/fulltext.html

Reference46 articles.

1. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012.

2. Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women. AIDS Behav. 2016;20(7):1470–7.

3. Escudero DJ, Kerr T, Operario D, Socias ME, Sued O, Marshall BD. Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2015;27(5):637–41.

4. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.

5. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Memo on Factors Associated with Perception of Stigma Attached to PrEP: Evidence from the Keeping It LITE Study;Sexes;2024-08-16

2. Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study;Journal of the Association of Nurses in AIDS Care;2024-08-13

3. Perceived Feasibility and Acceptability of HIV Prevention Research With Daily Oral PrEP Among Young Transgender Women (YTGW) Who Sell or Trade Sex in Bangkok and Pattaya, Thailand;AIDS Education and Prevention;2024-08

4. Improving Recruitment and Retention of Transgender Women in HIV Prevention Trials: Strategies to Make Trial Participation More Congruent with the Needs of Transgender Women;AIDS Research and Human Retroviruses;2024-07-31

5. Examining the Interplay Between Preexposure Prophylaxis (PrEP) and Gender-Related Stigmas as Barriers for PrEP Uptake Among Transgender Women in Tijuana, Mexico: A Mixed-Methods Study;AIDS and Behavior;2024-07-30